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SUMMARY : Clinical application of DNA analysis and a method of rapid DNA 
measurement were studied. DNA contents of 110 stage I lung carcinomas were measured, 
using paraffin embedded tissues, by means of flow cytometry. Aneuploidy was fond in 
73.6% of the tumors, and diploidy was found in 26.4%. In patients with DNA aneuploidy 
in T2N0, those treated with lobectomy had significantly longer survival time than those 
treated with limited operations (segmentectomy or partial resection of the lung). These 
results indicate that patients with DNA aneuploidy among patients with the disease Stage 
of T2N0 should not be treated with limited operations. The DNA content of 44 cases 
of benign lung diseases were also measured, and none of them were DNA aneuploid cases. 
It was concluded that DNA aneuploidy was a useful marker of malignant cells. 
Furthermore, as a surgical application of these results, interoperative DNA analysis is 
necessary ; so that a method of rapid DNA analysis was invented. It was possible to 
achieve DNA measurement within 15 minutes by using Triton X-100, RNase and PI, and 
the best DNA histogram was acquired by using 5% Triton X-100, 20 Kunitz/ml RNase 
and 50 µg/ml PI. These results indicate that it is possible to make interoperative DNA 
analysis and also it is useful to detect malignant cells and to determine the operative 
procedure.
       INTRODUCTION 
 Recently many clinical atudies of nuclear DNA 
measurement by means of flow cytometry have 
been reported, mainly assessing the effect of 
DNA content on prognosis. In lung carcinoma, 
investigators'-'), with a few exceptions',') 
reported that nuclear DNA content was a useful 
prognostic factor. Moreover Yasutake et al') 
demonstrated that patients with DNA diploidy 
survived significantly longer than those with 
DNA aneuploidy (p<0.001). Therefore clinical 
applications of DNA content in making a precise 
diagnosis and reasonable treatment are of great 
value. Malignant tumors have not only DNA 
aneuploidy but also diploidy ; so that it was
studied whether benign tumor has DNA 
aneuploidy or not. For the purpose of surgical 
treatment, DNA content should used as an indi-
cator to select the surgical method. Survival 
time for stage I lung carcinoma was estimated 
in terms of DNA ploidy and operation metods. 
Furthermore, for the purpose of clinical 
application, especially to Surgical operation, 
pre-operative or inter-operative DNA measure-
ment should be carried out. Recently, with ad-
vancing improvement of diagnostic techniques, 
small-sized lung tumors have not infrequently 
been detected, where it was difficult to obtain 
tumor cells preoperatively ; so that inter-
operative DNA analysis of lung carcinoma has 
become very important. If inter-operative DNA 
analysis is possible, nuclear DNA content can
be used as a diagnostic tool or as a factor to 
select the operative method. For the purpose 
of inter-operative DNA measurment, rapid DNA 
analysis is required ; therefore, the method of 
rapid DNA measurement was studied. This 
atudy aimed at assessment of validity of rapid 
DNA analysis of the basis of clinical results.
   MATERIALS AND METHODS 
1) Stage I lung carcinoma 
 One hundred and ten cases of stage I non-
small-cell lung carcinoma were examined. Their 
operations were performed at the First Depart-
ment of Surgery, Nagasaki University School of 
Medicine. Using paraffin-embedded tissue, 
DNA content was measured by means of flow 
cytometry. Single-cell suspension was prepared 
form paraffin-embedded tissues by the method 
of Schuttelo>. Shortly thick microtome sections 
(50 ,um x 3) from paraffin-embedded block was 
dewaxed using xylene and rehydrated by 
ethanol series and finally distilled water. A 
sample was incubated in 0.25% trypsin overnight 
and stained with propidium iodide (PI) 
according to the method of VindelOv">. A 
survival curve was drawn according to operative 
methods (limited operation and non-limited 
operation) and DNA ploidy. 
2) Benign lung disease 
 A total of 44 benign diseases 14 of tuber-
culosis, 6 of pneumonia, 3 of bronchiectasis, 4 
of bronchiolitis (diffuse pan bronchiolitis, etc.), 
6 of fibrosis (idiopathic interstitial pneu-
monia, interstitial pulmonary fibrosis, usual 
interstitial pneumonia, etc.) and 11 of other 
diseases (hamartonma, carcinoid, etc. ) were 
eligible for this study (Table 1). DNA content 
was measured, using paraffin-embedded tissues. 
3) Rapid DNA analysis 
 Peripheral blood lymphocyte (PBL), cell line 
(PC-9) and fresh clinical samples (lung cancer, 
stomach cancer and malignant thymoma) were 
processed. Single cell suspension of PBL,or cell 
line, was centrifuged, and a 3 mm cube of fresh 
clinical sample obtained by surgery was minced 
with scissors. These cells were suspended in 
1 ml Triton X-100/PBS (phosphate buffered 
saline) (0.1%, 1.0% or 5.0%). After pippeting and 
filtration through a nylon mesh (50,am), 1 ml
RNase/PBS (0, 20. 100, or 500 Kunitz/ml) was 
added. Subsequently, 2 ml PI/PBS (100 or 200 
,ug/ml) was finally added. 
  Furthermore, DNA content was measured at 
hours 0, 1, 2, 4, 6, and 8 after tumor resection; 
and it was measured at minutes 10, 20, 30, 40, 
60, 80, and 120 after sample preparation. 
5) Inter-operative DNA-content analysis 
 On 18 lung tumors DNA content was 
measured by the best method of rapid DNA 
analysis ; in 9 of 18 cases, pre-operative 
diagnosis was unknown, and in those cases 
inter-operative frozen-section pathological 
diagnosis was also performed. The remaining 
9 cases were lung carcinoma. All these cases 
were T1 or T2 cases. 
4) Flow cytometry and statistical method 
 Flow cytometric DNA analysis was performed 
on all samples. DNA contents were measured 
by flow cytometer (FACS 4) and DNA 
histograms were recorded. DNA diploidy has 
a single peak on a histogram, and DNA 
aneuploidy has two or more peaks accompanied 
by S+G2M. DNA index (DI) was calculated as 
the ratio of aneuploid to diploid Gl/0 peak 
channel. The number of cells per each was at 
least 10,000. The CV for the G1 peak was 
determined for each sample from the formula, 
CV =HM x 100/V X 2.35, where HM is the width 
of the G1 peak at half-maximum and V is the 
modal channel number of the G1 peak. 
 All above investigations were performed at 
room temperature. 
 Survival rate and significant difference were 
calculated and tested by Kaplan-Meier's me-
thod.
          RESULTS 
1) Stage I lung carcinoma 
 In the disease stage of T,No according to the 
general rules for the lung cancer study in 
surgery and pathology (Japanese - Reseach 
Society for lung cancer), there was no significant 
difference in survival time between patients 
treated with lobectomy and with limited opera-
tions (Fig. 1). On the other hand, in T2No, 
patients treated with lobectomy had signifi-
cantly longer survival time than those treated 
with limited operations (p<0.05) (Fig. 2). In
Fig. 1. Survival times according to operation 
      methods in T1No patients.
Fig. 2. Survival times according to operation 
      methods in T2No patients.
Fig. 3. Survival times according to operation method 
      and DNA nloidv in T2Nn patients.
patients with DNA diploidy in T2No, there was 
no significant difference between lobectomy and 
limited operation. In contrast in patients with 
DNA aneuploidy in T2No, those treated with 
lobectomy survived significantly longer than
those treated with limited operations (p<0.05) 
(Fig. 3). 
2) Benign lung disease 
 Of 44 cases of benign lung diseases, none of 
them were DNA aneuploid cases. (Table 1) 
3) Rapid DNA analysis 
 a) Triton X-100 concentration 
  One stomach cancer and three lung cancers 
were examined. DI and coefficient of variation 
(CV) was calculated. Using 0.1, 1.0, and 5.0% 
Triton X-100, mean CV was 4.4, 4.5 and 3.8, 
respectively. (Table 2) 
 b) RNase concentration 
 PC-9 cells were investigated. Channel number 
and CV of GO/1 peak channel were estimated. 
Channel numbers of RNase concentrations of 
0, 20, 100, and 500 Kunitz/ml were 51, 46, 45, and 
47, respectively ; CV were 3.4, 3.1, 3.7, and 3.3, 
respectively (Table 3). Furthermore, clinical 
samples (three lung carcinomas and one 
stomach carcinoma) were examined. CV of each 
RNase concentration (20, 100, and 500 Kunitz/ml) 
was 4.4, 4.4 and 4.3 respectively (Table 4). 
 c) PI concentration 
 PC-9 was used. Peak channel number and 
CV was not changed by PI concentration (100 
or 200 ,ug/m l). 
4) Resection-DNA measurement interval 
 Lung-cancer tissues were used. CV at each
Table 1. DNA ploidy of benign lung disease. 
      Disease DNA diploidy DNA aneuploidy 
 Tuberculosis 1 4 0 
  Pneumonia 6 0 
  Bronchiectasis 3 0 
 Bronchiolitis 4 0 
   (diffuse pan bronchiolitis. etc) 
 Fibrosis 6 0 
    
idiopathic interstitial pneumonia 
    
interstitial pulmonary fibrosis 
     usual interstitial pnecumon ia, etc. 
 Other benign region 1 1 0 
    (hamartoma, c rcinoid, etc.) 
            Total 44 0
Table 2. CV for each Triton X-100 contents of 4 
        clinical samples. 
Content of CV 
Triton X-100 Case 1 2 3 4 mean 
  0.1 % 4.1 3.7 5.7 3.9 4.4±0.9 
   1.0 % 4.8 3.6 5.6 3.9 4.5±0.9 
  5.0 % 3.5 3.7 4.9 3.0 3.8±0.8
Table 3. Channel number of GO/1 peak and CV for 
        each RNase contents of a cell line. 
  Content of Channel number CV 
 RNase of GO/1 peak 
    0 Ku/ml 51 3.4 
   20 46 3.1 
  100 45 3.7 
  500 47 3.3
Table 5. CV and channel number of GO/1 peak for 
         several resection-measurement interval. 
                      Time after resection (hrs) 
            0 1 2 4 6 8 
 CV 3.0 3.4 3.0 3.0 3.4 4.5 
 Channel number 53 52 51 51 51 53 
 of GO/1 peak 
                                     (NSCLC, room temp.)
Table 4. CV for each RNase contents of 4 clinical 
         samples. 
 Content of CV 
 RNase Case 1 2 3 4 mean 
  20 Ku/ml 4.1 3.7 5.7 3.9 4.4±0.9 
 100 4.5 3.5 5.9 3.7 4.4±1.1 
 500 5.5 3.4 5.0 3.4 4.3±1.1
Table 6. CV and DNA index for several prepar-
         ation-measurement interval of PBL and a 
        cell line. 
                 Time after sample prepartion (min) 
           0 10 20 30 40 60 80 120 
 CV PBL 2.2 2.3 2.2 2.5 2.8 2.5 3.0 2.6 
    cell line 2.1 2.1 2.3 2.6 2.5 2.7 2.9 2.6 
 DNA index 1.6 1.7 1.7 1.6 1.7 1.7 1.7 1.7 
                                        (PBL, Cell line)
time after resection, (0, 1, 2, 4, 6 and 8hrs) was 
3.0, 3.4, 3.0, 3.0 3.4, and 4.5, respectively. Peak 
channel number at those times was 53, 52, 51, 
51, 51 and 53, respectively. (Table 5). 
5) Sample preparation-DNA measurment inter-
val 
 First PBL and PC-9 cell were used. The 
results are showm in Table 6. CV and DI were 
stable without respect to the time after sample
Table 7. CV and DNA index for several time after 
        sample preparation of a clinical sample. 
                   Time after sample preparation (min) 
           0 10 20 30 40 60 80 120 
 CV 3.6 3.9 4.3 4.4 4.8 5.1 5.3 7.1 
 DNA index 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 
                                           clinical sample
               Table 8. Inter-operative DNA content analysis of 18 cases. 
No. case pre-op, diag. T n ploidy*' CV frozen. diag. path. 
  1. T. K. 67M - 1 0 D 4.9 Adeno. Adeno. 
  2. N. T. 81M - 1 0 A 5.3 Adeno. Adeno. 
  3. H. Y. 55F Adeno. 1 0 A 3.8 - Adeno. 
  4. C. 1. 63M - 1 0 A 4.9 Sq. Sq. 
  5. G. N. 57M Adeno. 1 2 A 4.0 - Adeno. 
  6. K. T. 53F Adeno. 1 0 A 8.5 - Adeno. 
  7. S. M. 76M Adeno. 1 0 A 5.2 - Adeno. 
  8. N. 0. 79M - 1 0 A 5.4 Adeno. Adeno. 
  9. C. K. 73M Adeno. 2 0 D 6.1 - Ad.Sq. 
 10. N. N. 77M Sq. 2 0 A 5.3 - Sq. 
 11. S. M. 70M Adeno. 2 0 D 8.1 - Adeno. 
 12. Y. S. 65M Sq. 2 0 A 5.7 - Sq. 
 13. M. T. 67M Sq. 2 2 A 5.9 - Sq. 
 14. S. K. 64M - D Benign. Hamartoma 
 15. K. S. 55F - D 3.3 Tb. Tb. 
 16. H. N. 58M - 1 0 A 2.6 Adeno. Adeno. 
 17. K. Y. 64H - - - A 7.1 Benign. Osteosarcoma 
 18. T. N. 55F - 2 0 A 4.7 Adeno. Adeno. 
 1. D : DNA diploidy, A : DNA aneuploidy
preparation. 
 Subsequently, lung carcinoma tissues were 
used. The results are shown in Table 7. DI 
was stable, but CV worsened with time after 
sample preparation. 
6) Inter-operative DNA content analysis The 
results are shown in Table 8. Five of 18 cases 
were of DNA diploidy and the others were of 
aneuploidy. Five diploid cases consisted of 3 
lung carcinomas and 2 benign tumors. Sixteen 
malignant tumors (final pathological diagnosis) 
consisted of 3 diploid tumors and 13 aneuploid 
tumors. All aneuoloid tumors were diagnosed 
as malignant by histopathology (final). Two 
benign tumors (final pathological diagnosis) 
were diploid. Frozen-section diagnosis was 
performed on 9 cases. Three of 9 cases were 
diagnosed as benign by frozen section, but one 
of these 3 cases was aneuploid. This aneuploid 
(but benign as diagnosed by frozen section) case 
was of osteosarcoma. In all these cases, only 
20 minutes were required, from receiving the 
sample to reporting the results to the surgeon.
         DISCUSSION 
 Yasutake et a1.9 reported that NSCLC con-
sisted of 81.5% aneuploid and 18.5% diploid cases 
and DNA ploidy was a valid prognostic tool on 
non-small-cell lung carcinoma (NSCLC), 
especially on stages I and II. The relationship 
between survival time and operative methods 
was evaluated in accordance with DNA ploidy 
analysis. Tomita et al. reported that node 
negative tumors smaller than 2.5 cm was a 
suitable case for limited operations"). But even 
if the tumor size was larger than 2.5 cm, 
surgeons often encountered patients who were 
not tolerable for the standard operation because 
of the high risk. In this study the results 
indicated that DNA aneuploid cases in T2No, 
should not be treated with limited operations 
if possible. This means that nuclear DNA 
analysis is unavoidable means for the selection 
of operation method. 
 On the other hand, detection of malignant 
cells by nuclear DNA contents is made by the 
fact that DNA aneuploidy must not be ob-
seved in benign tumors. Barlogie131, Danesi4) and 
Buchner14) reported that all cases (121, 77, and
 776 cases) of benign tumors were DNA diploid. 
 In this study 44 benign lung diseases were all 
 diploid cases. Although interstitial pulmonary 
 fibrosis and idiopathic interstitial pneumonia 
 are related to lung cancer 11-17 ), DNA aneuploidy 
 was not observed in any of these cases. 
 However, chromosomal analysis of solid tumor 
 was relatively difficult 18, 19), Teyssier et a1.201 
 reported that numerical chromosomal aberra-
 tion was observed in colon adenomas. But even 
 if abnormal peak was observed in benign 
 diseases, S+G2M may not be indicated on the 
 histogram. The results indicated that analysis 
 in nucler DNA content was available for the 
 detection of the malignant cells. On the other 
 hand, if the examined tumors were DNA diploid, 
 it would not represent a benign tumor only : it 
 meant a benign tumor or a malignant tumor 
 which had a low malignant potential. But if 
 the examined tumors were DNA diploid, one or 
 more samples should be tested because of tumor 
 cell heterogeneity. Thus, although determina-
 tion of DNA ploidy is a useful diagnostic tool, 
 pathologic examination can not be replaced by 
 DNA ploidy analysis. in lung cancers, however, 
 DNA aneuploidy is so frequent (more than 80%) 
 that aneuploid pattern is a suitable marker of 
 malignancy. 
   Pre-operative or inter-operative DNA mesure-
 ment is useful for selection of the opertative 
 method as well as for the help of inter-operative 
 pathological diagnosis by fronzen section. 
 Several papers on pre-operative DNA diagnosis 
 have been published'), but no reports of 
 inter-operative DNA analysis have been studied.
 The method of rapid DNA analysis, using Triton 
 X-100, RNase and PI, was reperted by Taylor 
 et al.21 ). In this study, further inter-operative 
 DNA measurment was studied. With the use 
 of 5% Triton X-100, the best CV was obtained. 
 It is a major factor that high content of Triton 
 X could dissolve damaged cells, erythrocytes or 
 others and subsequently could yield a large 
 number of cells from solid tumors. Especially, 
 on clinical samples which contain damaged cells 
 or erythrocytes, the use of 5% Triton X-100 is 
 the best. Channel number was changed with 
 or without RNase, this was due to the presence 
 of nuclear double-strand RNA, as it was stained 
 with PI of an intercalating dye. But RNase was
not so much required. Fifty ug/ml (final) PI 
were quite enough to fill up double-strand DNA. 
It was revealed that the best combination was 
1 ml 5% Triton X-100, 1 ml 20 Kunitz/ml RNase 
and 2 ml 100 ,ug/ml PI, From 0 to 6 hours after 
tumor resection, CV and channel number were 
stable. Over 8 hours after resection, CV was 
enlarged because autolysis had begun. 
Therefore, DNA content should be measured 
within 6 hours. For interoperative analysis it 
was not a problem, With the time after sample 
preparation, CV was gradually enlarged, and 120 
minutes later, histogram was not available on 
clinical sample, but it was used for rapid DNA 
analysis from the reason that correct results 
were acquired even in short incubation time. 
On the other hand, concerning cell line or PBL, 
CV was stable without respect to the time after 
sample preparation. Interstitial tissues may 
induce lytic change of cells or cell-cluster 
formation. Because only 20 minutes were 
required from sample preparation to reporting 
the results to the surgeon, inter-operative DNA 
measurement was clinically feasible and valid 
in clinacal_ use. Actually, on 18 lung tumors, 
DNA content was easily and rapidly measured 
and in some of them malignant cells were 
determind by nuclear DNA ploidy. 
 Recently with the improvement of diagno-
sis, many early stages of lung tumors were 
detedcted, and with prolongation of lifespan, 
surgery for elderly and highly risky patients has 
increases so that it is nesessary to select limited 
or non limited operations with an aid of inter-
operative measurment of DNA ploidy. For these 
reasons inter-operative rapid DNA analysis is 
of great benefit to minimize the operative insult 
effectively. 
 Clinical application of nuclear DNA content 
analysis, eapecially application to select surgical 
methods, was studied. This study suggests that 
inter-operative DNA analysis is of great value 
to confirm the diagnosis from frozen section and 
to select the operative methods on lung tumors. 
High quality DNA histograms could be obtained 
with this method. It is, therefore, emphasized 
that this method is very useful not only for 
inter-operative meafurement but also for con-
ventional DNA content measurement.
     ACKNOWLEDGMENT 
 The auther wishes to express his sincere 
gratitude to Prot. Masao Tomita, The First 
Department of Surgery, Nagasaki University 
School of Medicine, for his kind guidance in the 
study and review of paper. Thanks are also 
due to Dr. Y. Tagawa and to all the staff 
members of The First Department of Surgery, 
Nagasaki University School of Medicine.
         REFERENCES 
1) Volm, M., Hahn, E. W., Mattern, J., et al.: 
   Five-year follow-up study of independent clinical 
   and flow cytometric prognostic factors for the 
   survival of patients with non-small cell lung 
   carcinoma. Cancer Res. 48: 2923-2928, 1988. 
2) Blondal, T. and Lindgrem, A.: Fluorescence 
   cytophotometric measurment of nuclear DNA in 
   adenocarcinoma of the lung: Relation of 
  proliferative activity and DNA ploidy to 
   prognosis. Anal Quant Cytol. 3:225-232, 1982. 
3) Zimmerman, P. V., Hawson, G. A. T., Bint, M.H., 
   et al.: Ploidy as a prognostic determinant in 
   surgically treated lung cancer. Lancet 2 : 530-533, 
  1987. 
4) Danesi, D. T., Teodori, L., Mauro, F., et al.: 
   Prognostic significance of flow cytomety in lung 
   cancer : A 5 year study. Cancer 60: 844-854, 1987. 
5) Yamaoka, N., Uchiyama, Y., Azuma, K., et al.: 
   Flow cytometric nuclear DNA analysis in 
   resected primary non-smallcell lung carcinomas
   and its relationship to malignant intensity. 
   Lung Cancer 30: 9-18, 1990. 
6) Haneda H., Isobe, H., - Miyamoto, H., et al.: 
   Analysis of nuclear DNA content in non small 
   cell lung cancer : A comparison between DNA 
   index and prognosis. Oncologia 22: 62-68, 1989. 
7) Bunn, P. A. J., Carney, D. N., Gazdar, A. F., et al.: 
  Diagnostic and biological implications of flow 
   cytometric DNA content analysis in lung cancer. 
   Cancer Res. 43: 5026--5032, 1983. 
8) Cibas, E. S., Melamed, M. R., Zaman, M. B., et al.: 
   The effect of tumor size and tumor cell DNA 
   content on the survival of Patients with stage 
   I adenocarcinoma of the lung. Cancer 63: 1552-
  1556, 1989. 
9) Yasutake, T., Tagawa, Y., Ishikawa, K., et al.: 
  Significance of rapid DNA analysis of lung
   cancer cells at operation. FCM-cell biology 2: 
  52-57, 1990. 
10) Schutte, B., Reynders, M. M. J., Bosman, F.T., et 
   al.: Flow cytometric determination of DNA
  ploidy level in nuclei isolated from paraffin-
   embedded tissue. Cytometry 6:26-30, 1985. 
11) VindelWv, L. L., Christensen, I. J. and Nissen, N. 
   I.: A detergent-trypsin method for the pre-
   paration of nuclei for flow cytometric DNA 
   anlysis. Cytometry 3:323-327, 1983. 
12) Tomita, M., Ayabe, H., Kawahara, K., et al. 
   Limited operation in the treatment of lung 
   carcer. Surgical Therapy 58:6-8, 1988. 
13) Barlogie, B., Drewinko, B., Schumann, J., et al.: 
   Cellular DNA content as a marker of neoplasia 
   in man. Am J Med. 69:195-203, 1980. 
14) Buchner, T., Hiddeman, W., Wormann, B., et 
   al.: Differential pattern of DNA-aneuploidy in
   human malignancies. Pathe. Res. Pract. 179: 310-
  317, 1985. 
15) Kawai, T., Yakumaru, K., Suzuki, M., et al.: 
  Diffuse interstitiaal pulmonary fibrosis and lung 
   cater. Acta Pathol, Jpn. 37: 11-19, 1987.
16) Okano, H., Tanimoto, H., Nakata, K., et al.: Lung 
   cancer associated with idiopathic interstitial 
   pneumonia. J. J. A. T. S. 48: 189-198, 1989. 
17) Ninoyama, K., Matsubara, Y., Ikeda, T., et al.: 
   Clinical study of eight cases with lung cancer 
   accompanying idiopathic interstitial pneu-
   monia. Respiration 8:549 552, 1989. 
18) Atkin, N. B.: Solid tumor cytogenetics, progress 
   since 1979. Career Genet Cytogenet 40: 3-12, 1989. 
19) Yasutake, T., Tagawa, Y., Miyashita, K., et al.: 
   Study of fluorescence in situ hybrization for 
   detection of chromosome aberration. Human 
   Cell 2:436-438, 1989. 
20) Teyssier, J. R. and Ferre, D.: Frequent clonal 
   chromosomal changes in human nonmalig-
   nant tumors. Int. J. Cancer 44: 828-832, 1989. 
21) Taylor, I. W.: A rapid single step staining 
   technique for DNA analysis by flow micro-
   fluorimetry. J. Histochem Cytochem 28: 1021-1024, 
  1980.
